September 13, 2004Circulation
Renin-Angiotensin System and Angiotensin Receptor Blockers in the Metabolic Syndrome
Population
Patients with metabolic syndrome (MetS)
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
No immediate practice change for metabolic syndrome; leaves open whether angiotensin antagonists improve outcomes in prospective trials.
Structured PICO
P
Population
Patients with metabolic syndrome (MetS)
I
Intervention
Angiotensin antagonists (ACE inhibitors, ARBs)
This review highlights the pathophysiological cross-talk between angiotensin II and insulin signaling in metabolic syndrome, suggesting a potential therapeutic role for angiotensin antagonists.
Cite This Study
Prasad et al. (2004) studied this question.